Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jaguar Health Inc (NQ: JAGX )

1.015 +0.035 (+3.57%)
Streaming Delayed Price Updated: 11:18 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jaguar Health Inc

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, CA / ACCESSWIRE / October 29, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that, effective October 25, 2021, the Company granted nonstatutory... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
64 Biggest Movers From Yesterday
Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares jumped 83.4% to close at $5.30. Siyata Mobile released their Q2 earnings on an October 15th call that included CEO Marc... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Nurix Therapeutics (NASDAQ:NRIX) stock moved upwards by 15.4% to $33.42 during Wednesday's regular session. Trading volume for Nurix Therapeutics's stock... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Bio-Path Holdings (NASDAQ:BPTH) shares moved upwards by 9.69% to $5.43 during Wednesday's pre-market session. The company's market cap stands at $37.7... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Jaguar Health (NASDAQ:JAGX) shares increased by 14.64% to $2.08 during Monday's regular session. The current volume of 7.2 million shares is 300.39% of Jaguar... 
Via Benzinga
Italian Government Clears Merger Plan of Dragon SPAC S.p.A. and Jaguar Health's Italian Subsidiary Napo EU S.p.A. for Closing
Merger expected to be effective within a week The combined entity will be named Napo EU S.p.A. Merger effects the exclusive license agreement between Jaguar and Napo EU S.p.A. including up-front... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
60 Biggest Movers From Yesterday
Gainers Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) shares surged 308.1% to settle at $9.59 on Tuesday after the company signed an agreement with Waas Group for the... 
Via Benzinga
Jaguar Health Provides Updates on Crofelemer and Lechlemer Development Pipeline as well as Merger of Napo EU S.p.A. and Dragon SPAC S.p.A.
Dragon SPAC and Jaguar subsidiary Napo EU submit required notification to the Italian government in support of consummating the merger Results accepted for third-party, investigator-initiated Phase 2... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Jaguar Health Earnings Perspective: Return On Capital Employed
Jaguar Health (NASDAQ:JAGX) brought in sales totaling $385.00 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 32.1%, resulting in a loss... 
Via Benzinga
Jaguar Health's Founder and CEO Lisa Conte to Be Honored with Pure Earth Impact Award
Award celebrates Ms. Conte's 30-year, unrelenting commitment to supporting Indigenous communities in the Amazon and responsibly harvesting and commercializing the first-ever plant-based oral medicine... 
From Jaguar Health, Inc.
Via AccessWire
Topics Death
Exposures Death Product Safety
Jaguar Health Announces that Ladenburg Thalmann is Hosting R&D Showcase Webinar About Cancer Therapy-related Diarrhea on September 29, 2021
Leading oncologists discuss importance of supportive care for cancer patients to address debilitating diarrhea resulting from cancer therapy Virtual event 1:00 PM to 2:10 PM Eastern Registration open... 
From Jaguar Health, Inc.
Via AccessWire
Jaguar Health Receives "Complete" Letter from FDA for Last of Four Major Technical Sections for the Company's Application for Conditional Approval of Canalevia (Crofelemer) for Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar planning for launch of Canalevia™ for CID in dogs this December Canalevia is the first and only oral plant-based prescription drug candidate for CID in dogs SAN FRANCISCO, CA / ACCESSWIRE /... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
REMINDER: Jaguar Health to Host Investor Webcast Monday, September 20th at 8:30 AM Eastern Time
Click here to register for webcast Jaguar kicks off educational awareness contest in honor of Indigenous Peoples' Day; Click here to enter SAN FRANCISCO, CA / ACCESSWIRE / September 16, 2021 / Jaguar... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Orphan Drug Designation Application Submitted by Jaguar Health Subsidiary for Crofelemer for Short Bowel Syndrome with Intestinal Failure Accepted for Review by European Medicines Agency
The conditional marketing authorization pathway in Europe for crofelemer for this orphan disease is the initial focus of Napo EU under the license agreement between Napo EU and Napo Pharmaceuticals... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Xeris Pharmaceuticals (NASDAQ:XERS 
Via Benzinga
Jaguar Health Announces Closing of Private Placement Priced at a Premium to Market
Participating investors include Jaguar CEO and CFO, Dragon SPAC S.p.A. sponsor Josh Mailman, and plant-based pharmaceutical manufacturing pioneer Indena S.p.A. Company to host investor webcast Monday,... 
From Jaguar Health, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Product Safety Regulatory
JAGX Stock: What Is Going on With Jaguar Health Today?
Today, JAGX stock is surging higher on news of executive appointments, as well as the company's recent reverse stock split. 
Via InvestorPlace
Jaguar Health Appoints Karen Brunke, Ph.D. as Corporate and Business Development EVP and Chip Whitlow as Animal Health Products Marketing Director
Appointments represent Jaguar's focus on forging business development partnerships to advance crofelemer development and access and preparing for the expected near-term approval and commercialization... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Mid-Afternoon Market Update: Dow Falls Over 200 Points; RenovoRx Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded down 0.65% to 35,138.64 while the NASDAQ rose 0.13% to 15,383.18. The S&P also fell, dropping 0.27% to 4,522.99. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Mid-Day Market Update: Gold Drops 2%; Pliant Therapeutics Shares Jump
Midway through trading Tuesday, the Dow traded down 0.76% to 35,098.84 while the NASDAQ rose 0.09% to 15,376.87. The S&P also fell, dropping 0.33% to 4,520.38. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
72 Biggest Movers From Yesterday
Gainers Mechel PAO (NYSE: MTL) shares climbed 56.3% to settle at $5.00 on Tuesday. The company recently reported Q2results, including a 43% quarter-over-quarter revenue growth.... 
Via Benzinga
45 Stocks Moving In Tuesday's Mid-Day Session
Gainers IronNet, Inc. (NYSE: IRNT) shares jumped 50.4% to $25.06 after jumping over 23% on Friday. Mechel PAO (NYSE: MTL) shares jumped 32.6% to $4.2443. The company recently... 
Via Benzinga
23 Stocks Moving in Tuesday's Pre-Market Session
Gainers IronNet, Inc. (NYSE: IRNT) rose 89.7% to $31.61 in pre-market trading after jumping over 23% on Friday. Mechel PAO (NYSE: MTL) shares rose 36.6% to $4.37 in pre-market... 
Via Benzinga
Jaguar Health Stock Is Trading Lower In Reaction To Reverse Stock Split
Jaguar Health Inc (NASDAQ: JAGX) will effect a reverse stock split of its issued and outstanding voting common stock at an exchange ratio of 1-for-3. The Company... 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Enveric Biosciences (NASDAQ:ENVB... 
Via Benzinga
Jaguar Health, Inc. Announces 1-for-3 Reverse Stock Split
- Reverse split approved by majority of common stock shareholders at December 2020 special meeting of stockholders - Shares of Jaguar common stock to begin trading on split-adjusted basis on September... 
From Jaguar Health, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Product Safety Regulatory
Jaguar Health Reports Voting Results from 2021 Annual Meeting of Stockholders
Proposals 1, 2, 4, 5 & 6 approved SAN FRANCISCO, CA / ACCESSWIRE / September 3, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's... 
From Jaguar Health, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Product Safety Regulatory
Jaguar Health Subsidiary Napo Pharmaceuticals Submits Late-Breaking Abstract for Consideration for Presentation at the 2021 IDWeek Annual Meeting
Exploratory study evaluating effects of crofelemer on gut microbiome SAN FRANCISCO, CA / ACCESSWIRE / August 23, 2021 / Napo Pharmaceuticals, the wholly-owned subsidiary of Jaguar Health, Inc.... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Jaguar Health Subsidiary Napo Pharmaceuticals Signs License Agreement with its Italian Subsidiary, Napo EU S.p.A., to Develop and Commercialize Crofelemer and Lechlemer in Europe
Per the terms of the agreement, Napo Pharmaceuticals will receive an upfront payment of $10 million payable in two installments following the anticipated merger of Napo EU and Dragon SPAC S.p.A. and is... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Jaguar Health Subsidiary Announces Completion of Additional Preclinical Study of Lechlemer (NP-300), the Company's Human Drug Product Candidate for Diarrhea Relief from Cholera and Other Acute Infectious Diarrhea
In support of planned Investigational New Drug application for lechlemer, Napo Pharmaceuticals, Jaguar's wholly owned subsidiary, received comprehensive animal toxicity preclinical services supported... 
From Jaguar Health, Inc.
Via AccessWire
Topics Death
Exposures Death Product Safety
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.